Gilenya (Multiple Sclerosis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Classification of Multiple Sclerosis 13
3.2 Symptoms 15
3.2.1 Prognosis 16
3.2.2 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis 18
4.2 Treatment Overview 21
4.2.1 Management of Acute Relapse 22
4.2.2 Treatment with Disease-Modifying Therapies 22
4.2.3 Symptomatic Therapies 25
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Gilenya/Imusera (fingolimod; FTY720) 29
6.1 Overview 29
6.2 Efficacy 30
6.3 Safety 31
6.4 SWOT Analysis 32
6.5 Forecast 34
7 Appendix 35
7.1 Bibliography 35
7.2 Abbreviations 39
7.3 Methodology 41
7.4 Forecasting Methodology 41
7.4.1 Diagnosed MS patients 41
7.4.2 Percent Drug-Treated Patients 42
7.4.3 General Pricing Assumptions 42
7.4.4 Individual Drug Assumptions 43
7.4.5 Generic Erosion 43
7.5 Physicians and Specialists Included in This Report 44
7.6 Primary Research – Prescriber Survey 45
7.7 About the Authors 46
7.7.1 Analysts 46
7.7.2 Global Head of Healthcare 47
7.8 About GlobalData 48
7.9 Contact Us 48
7.10 Disclaimer 48